Glutarate

Glutarate

SCHEMBL158774

O=C(O)CCCC(=O)O.O=C(O)CCCC(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC22A6 Q4U2R8 2/20 1.00
LMNA P02545 4/20 0.83
TSHR P16473 6/20 0.77
NFKB1 P19838 2/20 0.77
PMP22 Q01453 1/20 0.77
ALKBH5 Q6P6C2 1/20 0.67
SUCNR1 Q9BXA5 1/20 0.67
EGLN1 Q9GZT9 1/20 0.67
CAMK2A Q9UQM7 1/20 0.67
HDAC11 Q96DB2 4/20 0.62
KMT2A Q03164 2/20 0.62
GABRR3 A8MPY1 1/20 0.62
GABRP O00591 1/20 0.62
GABRD O14764 1/20 0.62
HDAC3 O15379 1/20 0.62
GABBR2 O75899 1/20 0.62
CYP1A2 P05177 1/20 0.62
THRB P10828 1/20 0.62
GABRA1 P14867 1/20 0.62
GABRB1 P18505 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Glutarate SCHEMBL7414 1.00
Glutarate SCHEMBL27601182 1.00 SLC22A6 (1.00) SLC22A6LMNATSHRNFKB1PMP22
Glutarate SCHEMBL6701735 1.00
Glutarate SCHEMBL106538 0.96 SLC22A6 (0.92) SLC22A6LMNATSHRNFKB1PMP22
Glutarate SCHEMBL5603986 0.96 SLC22A6 (0.92) SLC22A6LMNATSHRNFKB1PMP22
Glutarate SCHEMBL162952 0.96 SLC22A6 (0.92) SLC22A6LMNATSHRNFKB1PMP22
Glutarate SCHEMBL8618878 0.96 SLC22A6 (0.92) SLC22A6LMNATSHRNFKB1PMP22
Glutarate SCHEMBL20876932 0.96 SLC22A6 (0.92) SLC22A6LMNATSHRNFKB1PMP22
Glutarate SCHEMBL2067314 0.96 SLC22A6 (0.92) SLC22A6LMNATSHRNFKB1PMP22
Glutarate SCHEMBL9805513 0.96 SLC22A6 (0.92) SLC22A6LMNATSHRNFKB1PMP22

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108215366-A Solventfree resin and preparation method thereof, reagent preparation box and application 三星聚合物有限公司 2018-06-29 CN claimed
WO-2004089357-A2 ANTI-FUNGAL FORMULATION OF TRITERPENE AND ESSENTIAL OIL REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2004-10-21 WO claimed
WO-2002026762-A1 TRITERPENES HAVING ANTIBACTERIAL ACTIVITY REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2002-04-04 WO claimed
CN-114269951-B Diagnostic method for aesthetic deterioration of skin 欧莱雅 2024-12-27 CN disclosed
CN-117143793-B Method for producing 5-carbon compound or polymer thereof 清华大学 2024-09-10 CN disclosed
WO-2023243349-A1 BIODEGRADABLE SPHERICAL PARTICLES AND PRODUCTION METHDO THEREFOR 株式会社ダイセル 2023-12-21 WO disclosed
CN-117143793-A Method for producing 5-carbon compound or polymer thereof 清华大学 2023-12-01 CN disclosed
WO-2023181993-A1 BIODEGRADABLE FLATTENED PARTICLES, COSMETIC COMPOSITION AND METHOD FOR PRODUCING BIODEGRADABLE FLATTENED PARTICLES 株式会社ダイセル 2023-09-28 WO disclosed
WO-2023119927-A1 POROUS PARTICLE, COSMETIC COMPOSITION, AND PRODUCTION METHOD FOR POROUS PARTICLE 株式会社ダイセル 2023-06-29 WO disclosed
CN-114107156-B Recombinant escherichia coli for efficiently producing glutaric acid, construction method and application thereof 江南大学 2023-06-02 CN disclosed
US-20190214145-A1 Method and systems for creating and screening patient metabolite profile to diagnose current medical condition, diagnose current treatment state and recommend new treatment regimen KUREK ITZHAK (US) 2019-07-11 US disclosed
EP-1740930-A2 SCREENING FOR SOLID FORMS BY ULTRASOUND CRYSTALLIZATION AND COCRYSTALLIZATION USING ULTRASOUND S.S.C.I., Inc (US) 2007-01-10 EP disclosed
US-7012155-B2 Process for the production of carboxylic acids LONZA S.P.A. (IT) 2006-03-14 US disclosed
WO-2005089375-A2 SCREENING FOR SOLID FORMS BY ULTRASOUND CRYSTALLIZATION AND COCRYSTALLIZATION USING ULTRASOUND S.S.C.I., INC. (US) 2005-09-29 WO disclosed
WO-2005077377-A1 COMPOSITIONS THAT INCLUDE A TRITERPENE AND A CARRIER REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2005-08-25 WO disclosed
WO-2004089357-A2 ANTI-FUNGAL FORMULATION OF TRITERPENE AND ESSENTIAL OIL REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2004-10-21 WO disclosed
US-20030144549-A1 Aliphatic carboxylic acids of formulae (Ib) R1-COOH(Ia) and R2- COOH wherein R1 is tertiary C4-20-alkyl and R2 is selected from hydrogen and C1-6-alkyl, or R1 and R2 together are -(CH2)n- with n=3 to 10, are produced by oxidizing an LONZA S.P.A. (IT) 2003-07-31 US disclosed
EP-0211042-A1 LIPOSOME COMPOSITION AND METHOD COOPER-LIPOTECH, INC. (US) 1987-02-25 EP disclosed
WO-1986004232-A1 LIPOSOME COMPOSITION AND METHOD COOPER-LIPOTECH, INC. (US) 1986-07-31 WO disclosed
US-4419507-A BUTYLENE TEREPHTHALATE POLYMER EASTMAN KODAK COMPANY (US) 1983-12-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030144549-A1 Aliphatic carboxylic acids of formulae (Ib) R1-COOH(Ia) and R2- COOH wherein R1 is tertiary C4-20-alkyl and R2 is selected from hydrogen and C1-6-alkyl, or R1 and R2 together are -(CH2)n- with n=3 to 10, are produced by oxidizing an ADIPOR1, AKR1C3, FASN SLC22A6 786/4885LMNA 841/4885TSHR 1026/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.